Phase 2 Type 2 Diabetes Trial, RecruitingNCT07215559Sponsor: Eli Lilly and CompanyCondition: Type 2 Diabetes
Printed from Voxsanity (voxsanity.com.au) — NCT07215559 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who have been diagnosed with type 2 diabetes
People whose HbA1c blood sugar level (a measure of average blood sugar over several months) was between 7.5% and 10.5% at their screening appointment
People who have been managing their diabetes with diet and exercise alone, a stable dose of metformin, an SGLT2 inhibitor (a type of diabetes tablet), or a combination of these, for at least 3 months before screening
People whose body weight has been fairly stable (less than 5% change up or down) in the 3 months before screening
People with a BMI of 27 or higher at their screening appointment
Who may not be able to join:
People who have any type of diabetes other than type 2 diabetes
People who have had, or are planning to have, weight loss surgery (bariatric surgery), unless they had liposuction or a tummy tuck more than 1 year before screening
People who have had a heart attack, stroke, unstable chest pain, or were hospitalised for heart failure within the 3 months before screening
People who have an active cancer, an untreated cancer, or who have been in remission from a significant cancer for less than 5 years (certain minor skin cancers and some early-stage cancers may be exceptions — confirm with trial site)
People who have been prescribed certain hormone-based medications used for diabetes or weight management (including GLP-1 receptor agonists and related drugs) within the last 6 months (confirm with trial site for the full list)
People who have used certain other diabetes medications — including sulfonylureas, DPP-4 inhibitors, and others — within the 3 months before screening (confirm with trial site for the full list)
People who have used insulin to manage their blood sugar at any point in the past year (some short-term exceptions may apply — confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
CDH Research Institute Pty Ltd, Maroochydore,
07 5408 0900
Momentum Sunshine, Melbourne,
0395096166
AIM Research, Merewether,
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT07215559
Sponsor: Eli Lilly and Company
Phase: Phase 2
Status: Recruiting
Condition: Type 2 Diabetes
Trial contact: 317-615-4559
More information: https://clinicaltrials.gov/study/NCT07215559
Eligibility summary (AI generated)
Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who have been diagnosed with type 2 diabetes
People whose HbA1c blood sugar level (a measure of average blood sugar over several months) was between 7.5% and 10.5% at their screening appointment
People who have been managing their diabetes with diet and exercise alone, a stable dose of metformin, an SGLT2 inhibitor (a type of diabetes tablet), or a combination of these, for at least 3 months before screening
People whose body weight has been fairly stable (less than 5% change up or down) in the 3 months before screening
People with a BMI of 27 or higher at their screening appointment
Who may not be able to join:
People who have any type of diabetes other than type 2 diabetes
People who have had, or are planning to have, weight loss surgery (bariatric surgery), unless they had liposuction or a tummy tuck more than 1 year before screening
People who have had a heart attack, stroke, unstable chest pain, or were hospitalised for heart failure within the 3 months before screening
People who have an active cancer, an untreated cancer, or who have been in remission from a significant cancer for less than 5 years (certain minor skin cancers and some early-stage cancers may be exceptions — confirm with trial site)
People who have been prescribed certain hormone-based medications used for diabetes or weight management (including GLP-1 receptor agonists and related drugs) within the last 6 months (confirm with trial site for the full list)
People who have used certain other diabetes medications — including sulfonylureas, DPP-4 inhibitors, and others — within the 3 months before screening (confirm with trial site for the full list)
People who have used insulin to manage their blood sugar at any point in the past year (some short-term exceptions may apply — confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇷 Argentina
🇦🇺 Australia
Puerto Rico
🇺🇸 United States
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percent Change from Baseline in Body Weight
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.